Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Linear Formula:
H2NC6H3-2-(OH)CO2H
CAS Number:
Molecular Weight:
153.14
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
2090421
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
SMILES string
Nc1ccc(O)c(c1)C(O)=O
InChI key
KBOPZPXVLCULAV-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
mesalazine, mesalamine
manufacturer/tradename
EDQM
mp
275-280 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... ALOX5(240), PPARG(5468), PTGS1(5742), PTGS2(5743)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
5-Aminosalicylic acid is a peroxidase substrate suitable for use in ELISA procedures. This substrate produces a soluble end product that is brown in color and can be read spectrophotometrically at 450 nm. The reaction may be stopped with 3 N NaOH and read at 550 nm.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
No data available
flash_point_c
No data available
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
A B Hawthorne et al.
Alimentary pharmacology & therapeutics, 27(12), 1157-1166 (2008-04-04)
Significant number of patients with ulcerative colitis (UC) fail to comply with treatment. To review issues surrounding medication non-adherence in inflammatory bowel disease (IBD), including the clinical and health service implications in the UK, and discuss strategies for optimizing medication
Alexander C Ford et al.
The American journal of gastroenterology, 106(12), 2070-2077 (2011-09-07)
Maintenance therapy with 5-aminosalicylates (5-ASAs) is recommended in patients with quiescent ulcerative colitis (UC), but compliance rates are low. Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied
A Lyakhovich et al.
Alimentary pharmacology & therapeutics, 31(2), 202-209 (2009-11-07)
Mesalazine (mesalamine) (5-ASA) is considered an anti-inflammatory drug for the treatment of inflammatory bowel disease. It is well tolerated by most patients and induces mucosal healing specifically in ulcerative colitis. Besides its anti-inflammatory properties, 5-ASA has been studied for cancer
M S Harris et al.
Alimentary pharmacology & therapeutics, 33(9), 996-1009 (2011-03-10)
The use of topical therapy in the treatment of ulcerative colitis has declined in recent years despite evidence of good efficacy. To review US prescription trends for 5-aminosalicylic acid (5-ASA) since the US approval of Asacol extended-release oral mesalazine (mesalamine)
A H Steinhart et al.
Alimentary pharmacology & therapeutics, 25(12), 1389-1399 (2007-06-02)
To evaluate the effectiveness of pH 6-/pH 7-dependent and controlled-release mesalazines in maintaining medically and surgically induced Crohn's disease remission. A systematic search identified 13 randomized controlled trials (RCTs). The rate of symptomatic relapse (Crohn's disease activity index >150, or
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service